Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 20,862 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Completed No phase listed Observational Results available

Tumor: Breast Ratio Study

NCT02216136
View directory record Official record
Conditions
Breast Cancer, LCIS, DCIS
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 72 Years · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 15, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

NCT02009436
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 15, 2026, 6:45 PM EDT
Completed Phase 2 Interventional

Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia

NCT00054171
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
aminolevulinic acid hydrochloride
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 15, 2026, 6:45 PM EDT
Terminated No phase listed Observational

Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery

NCT02433171
View directory record Official record
Conditions
Brain Metastasis
Interventions
Standard of Care FDG-PET Imaging
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 15, 2026, 6:45 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Irritable Bowel Syndrome and Control Volunteers: Diet Challenge

NCT03983434
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Inulin
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 15, 2026, 6:45 PM EDT
Recruiting Phase 3 Interventional

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109
View directory record Official record
Conditions
High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
272
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 216 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 15, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Image-guided, Robotically Delivered Transcranial Magnetic Stimulation Treatment for Combat-Related Post-Traumatic Stress Disorder

NCT02853032
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Active repetitive transcranial magnetic stimulation, robotic arm, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 15, 2026, 6:45 PM EDT
Recruiting Phase 2 Interventional

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428
View directory record Official record
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Stanford, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses

NCT01143181
View directory record Official record
Conditions
Double-stranded DNA Virus
Interventions
Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Loma Linda, California • Los Angeles, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 15, 2026, 6:45 PM EDT
Not listed Not applicable Interventional

Carbon Monoxide Monitoring and Emergency Treatment

NCT00841165
View directory record Official record
Conditions
Carbon Monoxide Poisoning
Interventions
Continuous Positive Airway Pressure, Non-rebreather oxygen mask
Device
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 15, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy

NCT02357992
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Body Radiotherapy (SABR)
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 15, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

NCT00413036
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's
Interventions
lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Muscle Shoals, Alabama • Scottsdale, Arizona • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 15, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

NCT02045836
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Golden, Colorado • Wichita, Kansas • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 15, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

NCT02197234
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing, Pharmacokinetic sampling - simvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 15, 2026, 6:45 PM EDT
Terminated Not applicable Interventional

Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology

NCT05461599
View directory record Official record
Conditions
Depressive Symptoms, Major Depressive Disorder, Depression, Cardiology, Gastrointestinal Diseases, Depressive Disorder, Depressive Episode, Adolescent Behavior, Adolescent - Emotional Problem
Interventions
SparkRx Mobile App
Device
Lead sponsor
Limbix Health, Inc.
Industry
Eligibility
13 Years to 22 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 15, 2026, 6:45 PM EDT
Active, not recruiting Not applicable Interventional

PILOT Phase: BPD Study

NCT07223619
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 15, 2026, 6:45 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 15, 2026, 6:45 PM EDT
Completed No phase listed Observational

Bronchial Thermoplasty 10+ Year Study

NCT03243292
View directory record Official record
Conditions
Asthma
Interventions
Bronchial Thermoplasty
Other
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Los Angeles, California • Detroit, Michigan • Saint Paul, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 15, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

STEM-Parkinson's Disease

NCT04797611
View directory record Official record
Conditions
Parkinson Disease, Parkinson's Disease and Parkinsonism
Interventions
TNM Device
Device
Lead sponsor
Scion NeuroStim
Industry
Eligibility
18 Years to 85 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
22
States / cities
Scottsdale, Arizona • Los Angeles, California • Englewood, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 15, 2026, 6:45 PM EDT
Active, not recruiting Phase 1 Interventional

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

NCT05823571
View directory record Official record
Conditions
Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia, CML, Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Leukemia
Interventions
Itacitinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 6:45 PM EDT
Recruiting Not applicable Interventional

Advocacy, Partnership, Outreach, and Yielding Optimized Care for Oncology Patients

NCT07403981
View directory record Official record
Conditions
Colorectal Cancer
Interventions
CHW/P Navigator Support, Social Services Resource List
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00058019
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 15, 2026, 6:45 PM EDT
Recruiting Phase 2 Interventional

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT04472767
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Nivolumab, Ipilimumab, Cabozantinib, Transarterial Chemoembolization
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 15, 2026, 6:45 PM EDT
Not listed Phase 1 Interventional

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

NCT00062907
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Recombinant DNA- pVAX/L523S, Recombinant adenovirus- Ad/L523S
Biological
Lead sponsor
Corixa Corporation
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
5
States / cities
Ocoee, Florida • Dallas, Texas • Tyler, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2006 · Synced Oct 15, 2026, 6:45 PM EDT